Selective TACE with Irinotecan-loaded 40 μm Microspheres and FOLFIRI for Colorectal Liver Metastases: Phase I Dose Escalation Pharmacokinetic Study

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2019 Aug 3

PMID 31370815

Citations 8

Authors

Toshihiro Tanaka

Takeshi Sato

Hideyuki Nishiofuku

Tetsuya Masada

Shota Tatsumoto

Nagaaki Marugami

Toshio Otsuji

Masatoshi Kanno

Fumikazu Koyama

Masayuki Sho

Kimihiko Kichikawa

Affiliations

Soon will be listed here.

Abstract

Background: Efficacy of treatments for colorectal liver metastases after failure of first-line chemotherapy is limited. The aim of this study was to prospectively evaluate the feasibility, tolerability, and pharmacokinetics of selective transarterial chemoembolization (TACE) with irinotecan-loaded 40 μm microspheres combined with systemic FOLFIRI for colorectal liver metastases refractory to oxaliplatin regimen.

Methods: The dose escalation study was conducted in three patient groups with different amounts of irinotecan loaded (50, 75 and 100 mg per mL-microspheres). Selective catheterization was performed to embolize subsegments or segments of located tumors using TACE navigation system. FOLFIRI was administrated 7 days after TACE. Plasma concentration was measured before and time points after administration.

Results: Nine patients successfully underwent a total of 22 TACE procedures. Dose-limiting toxicity did not appear at any level. The overall response rate was 55.6%. The median progression free and overall survival were 8.1 and 18.2 months, respectively. The AUC and C of plasma SN-38 per 1 mg injected irinotecan dose were significantly higher in irinotecan-loaded microspheres compared with FOLFIRI (P = 0.009 and P < 0.001, respectively).

Conclusion: Selective TACE using 40 μm irinotecan-loaded microspheres combined with systemic FOLFIRI was feasible and safe even when a high dose of irinotecan was loaded. Irinotecan-loaded microspheres resulted in a higher plasma concentration and AUC of SN-38 than treatment with FOLFIRI. Further large scale trials to evaluate the efficacy are mandatory.

Trial Registration: University Hospital Medical Information Network (UMIN) Clinical Trials Registry, Registration number; UMIN000015367 ; Registered date; 08,10,2014.

Citing Articles

Liver-Directed Therapy Combined with Systemic Therapy: Current Status and Future Directions.

Young S, Hannallah J, Goldberg D, Khreiss M, Shroff R, Arshad J Semin Intervent Radiol. 2024; 40(6):515-523.

PMID: 38274222 PMC: 10807971. DOI: 10.1055/s-0043-1777711.

Efficacy and Safety of Liver Chemoembolization Procedures, Combined with FOLFIRI Chemotherapy, in First-Line Treatment of Metastatic Colorectal Cancer in Patients with Oncogene Mutations.

Szemitko M, Falkowski A, Modrzejewska M, Golubinska-Szemitko E Cancers (Basel). 2024; 16(1).

PMID: 38201500 PMC: 10778126. DOI: 10.3390/cancers16010071.

Prospective Series of Transarterial Chemoembolization of Metastatic Colorectal Cancer to the Liver with 30-60 μm Microspheres Loaded with Irinotecan.

Malagari K, Kiakidis T, Moschouris H, Charokopakis A, Vergadis C, Alevisopoulos N Cardiovasc Intervent Radiol. 2023; 46(7):880-890.

PMID: 37337059 DOI: 10.1007/s00270-023-03446-6.

Combined CT-guided high-dose-rate brachytherapy (CT-HDRBT) and transarterial chemoembolization with irinotecan-loaded microspheres improve local tumor control and progression-free survival in patients with unresectable colorectal liver metastases....

Friedrich S, Busch F, Jonczyk M, Wieners G, Boning G, Ludemann W J Contemp Brachytherapy. 2023; 15(1):15-26.

PMID: 36970444 PMC: 10034730. DOI: 10.5114/jcb.2023.125480.

Safety, Feasibility and Technical Considerations from a Prospective, Observational Study-CIREL: Irinotecan-TACE for CRLM in 152 Patients.

Helmberger T, Lucatelli P, Pereira P, Gjoreski A, Jovanoska I, Bansaghi Z J Clin Med. 2022; 11(20).

PMID: 36294499 PMC: 9604674. DOI: 10.3390/jcm11206178.

References

Herben V, Schellens J, Swart M, Gruia G, Vernillet L, Beijnen J . Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors. J Clin Oncol. 1999; 17(6):1897-905. DOI: 10.1200/JCO.1999.17.6.1897. View

Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D . FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2003; 22(2):229-37. DOI: 10.1200/JCO.2004.05.113. View

Fuse N, Doi T, Ohtsu A, Yano T, Hamamoto Y, Minashi K . Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer. Int J Clin Oncol. 2008; 13(2):144-9. DOI: 10.1007/s10147-007-0737-z. View

Demachi H, Matsui O, Takashima T . Scanning electron microscopy of intrahepatic microvasculature casts following experimental hepatic artery embolization. Cardiovasc Intervent Radiol. 1991; 14(3):158-62. DOI: 10.1007/BF02577719. View

Bonomo G, Pedicini V, Monfardini L, Della Vigna P, Poretti D, Orgera G . Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc Intervent Radiol. 2009; 33(3):552-9. DOI: 10.1007/s00270-009-9752-y. View

Martin R, Howard J, Tomalty D, Robbins K, Padr R, Bosnjakovic P . Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry. Cardiovasc Intervent Radiol. 2010; 33(5):960-6. DOI: 10.1007/s00270-010-9937-4. View

Martin R, Joshi J, Robbins K, Tomalty D, Bosnjakovik P, Derner M . Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol. 2010; 18(1):192-8. DOI: 10.1245/s10434-010-1288-5. View

Dreher M, Sharma K, Woods D, Reddy G, Tang Y, Pritchard W . Radiopaque drug-eluting beads for transcatheter embolotherapy: experimental study of drug penetration and coverage in swine. J Vasc Interv Radiol. 2011; 23(2):257-64.e4. PMC: 3360470. DOI: 10.1016/j.jvir.2011.10.019. View

Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P . Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012; 32(4):1387-95. View

10.

Lewis A, Holden R, Chung S, Czuczman P, Kuchel T, Finnie J . Feasibility, safety and pharmacokinetic study of hepatic administration of drug-eluting beads loaded with irinotecan (DEBIRI) followed by intravenous administration of irinotecan in a porcine model. J Mater Sci Mater Med. 2012; 24(1):115-27. PMC: 3540360. DOI: 10.1007/s10856-012-4768-2. View

11.

Jones R, Dunne D, Sutton P, Malik H, Fenwick S, Terlizzo M . Segmental and lobar administration of drug-eluting beads delivering irinotecan leads to tumour destruction: a case-control series. HPB (Oxford). 2012; 15(1):71-7. PMC: 3533714. DOI: 10.1111/j.1477-2574.2012.00587.x. View

12.

Kochi M, Akiyama Y, Aoki T, Hagiwara K, Takahashi T, Hironaka K . FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study. Cancer Chemother Pharmacol. 2013; 72(5):1097-102. DOI: 10.1007/s00280-013-2292-9. View

13.

Tanaka T, Nishiofuku H, Hukuoka Y, Sato T, Masada T, Takano M . Pharmacokinetics and antitumor efficacy of chemoembolization using 40 µm irinotecan-loaded microspheres in a rabbit liver tumor model. J Vasc Interv Radiol. 2014; 25(7):1037-1044.e2. DOI: 10.1016/j.jvir.2014.04.005. View

14.

Akinwande O, Philips P, Duras P, Pluntke S, Scoggins C, Martin R . Small versus large-sized drug-eluting beads (DEBIRI) for the treatment of hepatic colorectal metastases: a propensity score matching analysis. Cardiovasc Intervent Radiol. 2014; 38(2):361-71. DOI: 10.1007/s00270-014-1011-1. View

15.

Lewis A, Dreher M, OByrne V, Grey D, Caine M, Dunn A . DC BeadM1™: towards an optimal transcatheter hepatic tumour therapy. J Mater Sci Mater Med. 2015; 27(1):13. PMC: 4681748. DOI: 10.1007/s10856-015-5629-6. View

16.

Bhutiani N, Akinwande O, Martin 2nd R . Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases. World J Surg. 2015; 40(5):1178-90. DOI: 10.1007/s00268-015-3386-9. View

17.

Yamazaki K, Nagase M, Tamagawa H, Ueda S, Tamura T, Murata K . Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol. 2016; 27(8):1539-46. DOI: 10.1093/annonc/mdw206. View

18.

Kuramochi H, Ando M, Itabashi M, Nakajima G, Kawakami K, Hamano M . Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab. Cancer Chemother Pharmacol. 2017; 79(3):579-585. DOI: 10.1007/s00280-017-3255-3. View